遗传性维生素D降低与阿尔茨海默病风险
该研究采用孟德尔随机化方法,利用SUNLIGHT联盟的4个与25羟维生素D水平全基因组显著相关的SNP作为工具变量,在CaMos队列中验证其效应,并从IGAP联盟获取AD风险估计。结果显示,自然对数转换的25羟维生素D每降低1个标准差,AD风险增加25%(OR 1.25,95%CI 1.03-1.51,p=0.021),支持25羟维生素D为AD的因果风险因素。
要点
- 遗传预测的25羟维生素D降低与AD风险增加存在因果关联
- 25羟维生素D每降1个标准差,AD风险增加25%
- 结果支持通过随机对照试验探索维生素D补充对认知和AD风险的影响
核心结论
- 遗传学证据支持25羟维生素D是阿尔茨海默病的因果风险因素。
研究设计与样本
- 孟德尔随机化研究,工具变量来自SUNLIGHT联盟(N=33,996)的4个SNP。
- 在CaMos队列(N=2,347)中评估SNP对25羟维生素D的效应,AD风险估计来自IGAP联盟(17,008例AD患者和37,154例对照)。
主要发现
- SUNLIGHT联盟识别出4个与25羟维生素D全基因组显著相关的SNP,在CaMos中解释2.44%的方差。
- 孟德尔随机化分析显示,自然对数转换的25羟维生素D每降低1个标准差,AD风险增加25%(OR 1.25,95%CI 1.03-1.51,p=0.021)。
- 去除可能受多效性和人群分层影响的SNP后,敏感性分析结果基本不变。
临床怎么用
- 提示维生素D状态可能是AD的可干预风险因素,但需随机对照试验验证补充维生素D对认知和AD风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test whether genetically decreased vitamin D levels are associated with Alzheimer disease (AD) using mendelian randomization (MR), a method that minimizes bias due to confounding or reverse causation. METHODS: We selected single nucleotide polymorphisms (SNPs) that are strongly associated with 25-hydroxyvitamin D (25OHD) levels (p < 5 × 10-8) from the Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits (SUNLIGHT) Consortium (N = 33,996) to act as instrumental variables for the MR study. We measured the effect of each of these SNPs on 25OHD levels in the Canadian Multicentre Osteoporosis Study (CaMos; N = 2,347) and obtained the corresponding effect estimates for each SNP on AD risk from the International Genomics of Alzheimer's Project (N = 17,008 AD cases and 37,154 controls). To produce MR estimates, we weighted the effect of each SNP on AD by its effect on 25OHD and meta-analyzed these estimates using a fixed-effects model to provide a summary effect estimate. RESULTS: The SUNLIGHT Consortium identified 4 SNPs to be genome-wide significant for 25OHD, which described 2.44% of the variance in 25OHD in CaMos. All 4 SNPs map to genes within the vitamin D metabolic pathway. MR analyses demonstrated that a 1-SD decrease in natural log-transformed 25OHD increased AD risk by 25% (odds ratio 1.25, 95% confidence interval 1.03-1.51, p = 0.021). After sensitivity analysis in which we removed SNPs possibly influenced by pleiotropy and population stratification, the results were largely unchanged. CONCLUSIONS: Our results provide evidence supporting 25OHD as a causal risk factor for AD. These findings provide further rationale to understand the effect of vitamin D supplementation on cognition and AD risk in randomized controlled trials.
引用
- Mokry LE, Ross S, Morris JA, et al. Genetically decreased vitamin D and risk of Alzheimer disease. Neurology. 2016. PMID: 27856775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。